A Phase 3 trial investigating an adaptive web application for medication optimization in Heart Failure patients completed its primary data collection on December 1, 2025, having enrolled 225 participants.
Background
Heart failure (HF) is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs. Heart failure with reduced ejection fraction (HFrEF) is a specific type where the left ventricle's pumping capacity is weakened. Guideline-directed medical therapy (GDMT) is crucial for managing HFrEF, significantly improving patient outcomes and quality of life. However, optimizing GDMT can be complex, often requiring dose adjustments and careful monitoring, which can be challenging for both patients and clinicians. Digital health solutions, such as web applications, offer a potential avenue to support patients in adhering to and optimizing their medication regimens by providing personalized guidance and facilitating data analysis.
Trial design
The SmartHF study is a 12-week prospective, randomized, controlled, multicenter clinical trial conducted as a Phase 3 study. It enrolled 225 participants with Heart Failure (specifically HFrEF) to investigate the efficacy of an adaptive web application designed to facilitate GDMT optimization. Eligible participants were randomized in a 1:1 manner to either the web application intervention or a control group, stratified by site. The intervention involved an adaptive medication optimization web application that extracts and analyzes electronic health record (EHR) data using a computable medication optimization algorithm. This algorithm provides a medication quality score and aims to guide medication adjustments.
What this means
The primary completion of this Phase 3 trial signifies a significant milestone for the SmartHF study. With 225 participants, the trial has concluded its main data collection phase for evaluating an adaptive web application's role in optimizing medication for HFrEF patients. The successful completion of this phase moves the study closer to analyzing its primary outcomes, which will shed light on the application's potential to improve GDMT adherence and patient management in heart failure. The findings from this trial could inform future strategies for leveraging digital tools to enhance chronic disease management and medication optimization in real-world clinical settings.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT05858320, titled "The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients", was updated on December 1, 2025 on clinicaltrials.gov.